The U.S. Food and Drug Administration granted tentative approval for the 50th and 51st anti-retroviral drugs included under the President’s Emergency Plan for AIDS Relief (PEPFAR), which funds programs overseas.

The tentative approval was granted for nevirapine tablets, to be used in conjunction with other drugs to treat HIV-1 infection, and for the first ever fixed-dose drug intended to treat children less than 12 years of age. The latter is a twice-daily, triple-drug tablet that can be dissolved in water to help children who have difficulty swallowing pills.